IPOs & Listings
Beta Bionics Options Lock-Up With J.P. Morgan and Piper Sandler Consent Ends November 15, 2026
By News Desk ·
Key takeaways
- Beta Bionics options are locked up for 61 days, from September 15 to November 15, 2026.
- J.P. Morgan Securities and Piper Sandler must give written consent before lock-up parties can transfer shares.
- Beta Bionics raised a $172.5 million post-IPO equity round in September 2026, according to akta.pro records.
Certain options of Beta Bionics are subject to a lock-up agreement ending on November 15, 2026, covering 61 days from September 15, 2026, MarketScreener reported. The arrangement binds directors, executive officers and certain significant stockholders of the diabetes device maker.
How the Beta Bionics Lock-Up Works
Under the agreements signed with the underwriters before the offering began, each lock-up party may not, with limited exceptions, offer, pledge, sell or otherwise transfer shares of common stock or securities convertible into or exercisable or exchangeable for common stock during the restricted period. The prospectus sets that period at 60 days after its date. The lock-up parties need the prior written consent of J.P. Morgan Securities LLC and Piper Sandler & Co. to act.
Beta Bionics is a commercial-stage medical device company. Its iLet Bionic Pancreas is cleared by the U.S. Food and Drug Administration to use adaptive closed-loop algorithms to set every insulin dose without the user counting carbohydrates, and it is used to treat Type 1 diabetes. The company's offerings include iLet for Adults, iLet for Children, the Bionic Circle App and the iLet Simulator. Beta Bionics is in the early stages of developing a patch pump that adheres to the skin without tubing, and of developing a bihormonal configuration of the iLet.
Beta Bionics Funding History
Beta Bionics closed a $172.5 million post-IPO equity round in September 2026, according to akta.pro company records. The same records list a $60 million Series E round led by Wellington Management in November 2024, a $100 million Series D round led by Sands Capital and Omega Funds in September 2023, and a $57 million Series C round in February 2022. The records count 10 funding rounds and total funding of $526 million.
| Round | Date | Amount | Lead investors |
|---|---|---|---|
| Series C | February 2022 | $57 million | Eventide, Farallon Capital Management, Perceptive Advisors |
| Series D | September 2023 | $100 million | Sands Capital, Omega Funds |
| Series E | November 2024 | $60 million | Wellington Management |
| Post-IPO equity | September 2026 | $172.5 million | Not stated |
Beta Bionics Before the Lock-Up
Beta Bionics reported $35.5 million in net sales for the third quarter of 2026, driven by adoption of its automated insulin delivery platform, The Motley Fool reported in November 2026. The company received FDA clearance for its Mint patch pump, the same report said. In November 2026, Levi & Korsinsky alerted investors to a pending securities class action naming CEO Sean Saint and CFO Stephen Feider as defendants, according to Business & Financial.